Products for Research Use Only
RegisterLogin

Poseltinib

CAT: 0804-HY-109010-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109010-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Bruton tyrosine kinase (BTK) inhibitor. With an IC50 of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR) . Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis[1][2][3].
CAS Number
1353552-97-2
Product Name Alternative
HM71224; LY3337641
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
BMX Kinase; Btk; Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation; Protein Tyrosine Kinase/RTK
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/poseltinib.html
Concentration
10mM
Purity
98.08
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C=C)NC1=CC=CC(OC2=C(OC=C3)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=N2)=C1
Molecular Formula
C26H26N6O3
Molecular Weight
470.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Kim YY, et al. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017 Sep 26;19 (1) :211.|[2]Park JK, et al. HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Arthritis Res Ther. 2016 Apr 18;18:91. |[3]Byun JY, et al. Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection. Sci Rep. 2021 Sep 21;11 (1) :18671.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
BA6302-5.1Poseltinib
MBS3843905-01Poseltinib (HM71224, LY3337641)
A19450-2Poseltinib (HM71224, LY3337641) 2mg
A19450-100Poseltinib (HM71224, LY3337641) 100mg
A19450-50Poseltinib (HM71224, LY3337641) 50mg
A19450-1Poseltinib (HM71224, LY3337641) 1mg
A19450-10Poseltinib (HM71224, LY3337641) 10mg
A19450-5Poseltinib (HM71224, LY3337641) 5mg

Popular Products